The Centre for Probe Development and Commercialization (CPDC) at McMaster University in Hamilton, Ontario, announces that it has licensed the Centyrin® platform from Janssen Biotech, Inc. for exclusive use in combination with its radiopharmaceutical expertise to create novel nuclear imaging probes against immunotherapy drug targets.
Immunotherapy has become one of the most active areas in oncology where there is a need for better diagnostic tools to monitor patient response. Nuclear imaging probes are a special class of molecules that are administered to patients in order to visualize their cancers using non-invasive imaging devices such as PET scanners. Molecular probes can reveal characteristics about the disease that may help physicians select the optimal therapy for a patient and furthermore tell physicians very early on if a treatment is working.
“We are thrilled to combine the targeting and precision tuning capabilities of the Centyrin® platform with our expertise in radiopharmaceutical development to create novel tools with the potential to enhance immunotherapy drug development and further accelerate its use,” says Dr. John Valliant, founder and Chief Executive Officer of CPDC.
About the CPDC
The Centre for Probe Development and Commercialization (CPDC) is a world leader in the development and translation of new diagnostics, notably molecular imaging probes derived from medical isotopes. The CPDC has extensive experience using cyclotrons and innovative chemical methods to create next generation imaging technologies including companion diagnostics to new therapies. CPDC was created with funding from the Networks of Centres of Excellence (NCE) Centres of Excellence for Commercialization and Research (CECR) program, the Ontario Institute for Cancer Research and several industry partners. See www.imagingprobes.ca for more details.
About McMaster University
McMaster University, one of four Canadian universities listed among the Top 100 universities in the world, is renowned for its innovation in both learning and discovery. It has a student population of 30,000, and more than 170,000 alumni in 137 countries.
Hamilton, Ontario, November 16, 2018 – The Centre for Probe Development and Commercialization (CPDC) is proud to introduce the new Head of Business Development, Bruno Paquin, PhD. Bruno comes to us with years of experience in research and development and he brings with him extensive knowledge of scientific operations in life and health sciences, as
Hamilton, Ontario, October 3, 2018 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, today is announcing that its founder, Dr. John Valliant, has stepped down from his role as CEO to focus his time as the CEO of Fusion Pharmaceuticals. Dr. Valliant will
HAMILTON, Ontario, September 13, 2018 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, and the McMaster Nuclear Reactor facility (MNR), a leading research reactor program that provides a source of medical radioisotopes, announced today that they have signed an agreement to explore the